日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Effect of liver biopsy size on MASLD fibrosis assessment by second-harmonic generation/two-photon excitation fluorescence microscopy

肝活检大小对二次谐波生成/双光子激发荧光显微镜评估MASLD纤维化的影响

Field, Daniel T; Ren, Yayun; Akbary, Kutbuddin; Chng, Elaine; Tai, Dean; Naoumov, Nikolai V; Kleiner, David E; Fallowfield, Jonathan A; Kendall, Timothy J; Sanyal, Arun J

Digital quantitation of bridging fibrosis and septa reveals changes in natural history and treatment not seen with conventional histology

对桥接纤维化和间隔进行数字化定量分析,揭示了传统组织学无法观察到的自然病程和治疗变化。

Naoumov, Nikolai V; Kleiner, David E; Chng, Elaine; Brees, Dominique; Saravanan, Chandra; Ren, Yayun; Tai, Dean; Sanyal, Arun J

Tropifexor for nonalcoholic steatohepatitis: an adaptive, randomized, placebo-controlled phase 2a/b trial

托吡酯治疗非酒精性脂肪性肝炎:一项适应性、随机、安慰剂对照的 2a/b 期试验

Sanyal, Arun J; Lopez, Patricia; Lawitz, Eric J; Lucas, Kathryn J; Loeffler, Juergen; Kim, Won; Goh, George B B; Huang, Jee-Fu; Serra, Carla; Andreone, Pietro; Chen, Yi-Cheng; Hsia, Stanley H; Ratziu, Vlad; Aizenberg, Diego; Tobita, Hiroshi; Sheikh, Aasim M; Vierling, John M; Kim, Yoon Jun; Hyogo, Hideyuki; Tai, Dean; Goodman, Zachary; Schaefer, Felicity; Carbarns, Ian R I; Lamle, Sophie; Martic, Miljen; Naoumov, Nikolai V; Brass, Clifford A

Tropifexor plus cenicriviroc combination versus monotherapy in nonalcoholic steatohepatitis: Results from the phase 2b TANDEM study

托吡酯联合塞尼立维罗治疗非酒精性脂肪性肝炎与单药治疗的比较:来自 2b 期 TANDEM 研究的结果

Anstee, Quentin M; Lucas, Kathryn J; Francque, Sven; Abdelmalek, Manal F; Sanyal, Arun J; Ratziu, Vlad; Gadano, Adrian C; Rinella, Mary; Charlton, Michael; Loomba, Rohit; Mena, Edward; Schattenberg, Jörn M; Noureddin, Mazen; Lazas, Donald; Goh, George B B; Sarin, Shiv K; Yilmaz, Yusuf; Martic, Miljen; Stringer, Rowan; Kochuparampil, Jossy; Chen, Li; Rodriguez-Araujo, Gerardo; Chng, Elaine; Naoumov, Nikolai V; Brass, Clifford; Pedrosa, Marcos C

Alisporivir inhibition of hepatocyte cyclophilins reduces HBV replication and hepatitis B surface antigen production

Alisporivir通过抑制肝细胞环孢亲和素来减少HBV复制和乙型肝炎表面抗原的产生。

Phillips, Sandra; Chokshi, Shilpa; Chatterji, Udayan; Riva, Antonio; Bobardt, Michael; Williams, Roger; Gallay, Philippe; Naoumov, Nikolai V

Long-Term Telbivudine Treatment Results in Resolution of Liver Inflammation and Fibrosis in Patients with Chronic Hepatitis B

长期服用替比夫定可使慢性乙型肝炎患者的肝脏炎症和纤维化消退。

Hou, Jin-Lin; Xu, Daozheng; Shi, Guangfeng; Wan, Mobin; Goodman, Zachary; Tan, Deming; Xie, Qing; Chen, Chengwei; Wei, Lai; Niu, Junqi; Wang, Qinhuan; Ren, Hong; Wang, Yuming; Jia, Jidong; Bao, Weibin; Dong, Yuhong; Trylesinski, Aldo; Naoumov, Nikolai V

Early Viral Kinetics with Telbivudine, Tenofovir or Combination of Both in Immunotolerant Patients with Hepatitis B e Antigen-Positive Chronic Hepatitis B

在乙型肝炎e抗原阳性慢性乙型肝炎免疫耐受患者中,替比夫定、替诺福韦或二者联合用药的早期病毒动力学研究

Leung, Nancy W Y; Herrmann, Eva; Lau, George K K; Chan, Henry L Y; So, Tokutei M K; Zeuzem, Stefan; Dong, Yu; Trylesinski, Aldo; Naoumov, Nikolai V

The combination of alisporivir plus an NS5A inhibitor provides additive to synergistic anti-hepatitis C virus activity without detectable cross-resistance

阿拉泊韦与 NS5A 抑制剂的组合提供了协同抗丙型肝炎病毒活性的附加作用,且没有可检测到的交叉耐药性

Udayan Chatterji, Jose A Garcia-Rivera, James Baugh, Katarzyna Gawlik, Kelly A Wong, Weidong Zhong, Clifford A Brass, Nikolai V Naoumov, Philippe A Gallay

An engineered non-toxic superantigen increases cross presentation of hepatitis B virus nucleocapsids by human dendritic cells

一种工程化的无毒超抗原可增加人类树突状细胞对乙型肝炎病毒核衣壳的交叉呈递

Julie D McIntosh, Kristy Manning, Shilpa Chokshi, Nikolai V Naoumov, John D Fraser, P Rod Dunbar, John A Taylor

Novel mechanism of antibodies to hepatitis B virus in blocking viral particle release from cells

乙型肝炎病毒抗体阻断病毒颗粒从细胞释放的新机制

Neumann, Avidan U; Phillips, Sandra; Levine, Idit; Ijaz, Samreen; Dahari, Harel; Eren, Rachel; Dagan, Shlomo; Naoumov, Nikolai V